Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

AvKARE

US Class II Ongoing · initiated 2026-02-13

Failed Dissolution Specifications: This recall has been initiated due to an Out of Specification finding in dissolution.

Harbin Jixianglong Biotech Co., Ltd.

US Class II Ongoing · initiated 2026-02-13

CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution

Harbin Jixianglong Biotech Co., Ltd.

US Class II Ongoing · initiated 2026-02-13

CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution

Seasonique and Seasonale Tablets

Canada Type I Ongoing · initiated 2026-02-13

Product quality. Do not skip any doses or stop taking Seasonique or Seasonale.If your package is missing a blister card or any pills, return it to your pharmacy…

Slate Run Pharmaceuticals

US Class III Ongoing · initiated 2026-02-12

Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved s…

LEO PHARMA INC

US Class II Ongoing · initiated 2026-02-10

Lack of Assurance of Sterility: due to the presence of particulate matter in one unit from the lot, which lab tests have identified as wool fiber.

Meitheal Pharmaceuticals, Inc

US Class II Ongoing · initiated 2026-02-09

Defective Delivery System: Missing or duplicated needles within the injection kit

MAR-AMLODIPINE

Canada Type I Ongoing · initiated 2026-02-09

Product safety. Immediately check your medication bottle to ensure it only contains MAR-Amlodipine 5 mg tablets.MAR-Amlodipine 5 mg tablets are white to off-whi…

CEFAZOLIN FOR INJECTION, USP

Canada Type III Ongoing · initiated 2026-02-09

Labelling. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns…

TARO-CANDESARTAN

Canada Type II Ongoing · initiated 2026-02-09

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Fresenius Kabi Compounding, LLC

US Class II Ongoing · initiated 2026-02-05

Lack of Assurance of Sterility

Fresenius Kabi Compounding, LLC

US Class II Ongoing · initiated 2026-02-05

Lack of Assurance of Sterility

Fresenius Kabi Compounding, LLC

US Class II Ongoing · initiated 2026-02-05

Lack of Assurance of Sterility

Fresenius Kabi Compounding, LLC

US Class II Ongoing · initiated 2026-02-05

Lack of Assurance of Sterility

Fresenius Kabi Compounding, LLC

US Class II Ongoing · initiated 2026-02-05

Lack of Assurance of Sterility

SOMERSET THERAPEUTICS LLC

US Class II Ongoing · initiated 2026-02-04

Failed Impurities/Degradation Specifications - OOS impurities result observed during long term stability testing at product expiry (24 months) were above specs …

Annora Pharma Private Limited

US Class III Ongoing · initiated 2026-02-03

Presence of foreign tablets/capsules: one Pitavastatin tablet 1mg found in bottle of Pitavastatin tablets 2mg

Pro Numb Tattoo Numbing Spray LLC

US Class II Ongoing · initiated 2026-02-02

cGMP deviations

Pro Numb Tattoo Numbing Spray LLC

US Class II Ongoing · initiated 2026-02-02

cGMP deviations

Teva Pharmaceuticals USA, Inc

US Class II Ongoing · initiated 2026-01-29

Failed Dissolution Specifications

Teva Pharmaceuticals USA, Inc

US Class II Ongoing · initiated 2026-01-29

Failed Dissolution Specifications

Teva Pharmaceuticals USA, Inc

US Class II Ongoing · initiated 2026-01-29

Failed Dissolution Specifications

Teva Pharmaceuticals USA, Inc

US Class II Ongoing · initiated 2026-01-29

Failed Dissolution Specifications

SUN PHARMACEUTICAL INDUSTRIES INC

US Class II Ongoing · initiated 2026-01-27

Failed Viscosity Specifications: Out of Specification (OOS) [slightly lower than the limit] result in viscosity for Diclofenac Sodium Gel, 3%.

Granules Pharmaceuticals Inc.

US Class II Ongoing · initiated 2026-01-26

Presence of Foreign Tablets/Capsules